Bedford J L, Childs P J, Nordmark Hansen V, Mosleh-Shirazi M A, Verhaegen F, Warrington A P
Joint Department of Physics, The Institute of Cancer Research and the Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.
Br J Radiol. 2003 Mar;76(903):163-76. doi: 10.1259/bjr/42085182.
The commissioning of a Pinnacle(3) treatment planning system is described. Four Elekta linear accelerators were commissioned for external beam photons. Measured data were used to derive parameter values for the Pinnacle(3) beam model by (1). fitting a Monte Carlo model of the accelerator head to measured data and then extracting the parameters for the Pinnacle(3) beam model, and by (2). using the auto-modelling facility within Pinnacle(3). Both of these methods yielded dose distributions in accord with published recommendations. A separate small-field beam model, customized for an in-house compact blocking system, was also created, which satisfied appropriate acceptance criteria for stereotactically guided conformal brain treatments. Inhomogeneous, oblique, asymmetrical and irregular fields were also assessed, with calculated and measured doses agreeing to within +/-3%. Dose-volume histogram calculation was found to be accurate to within +/-5% dose or volume for a grid size of 4 mm x 4 mm x 4 mm, with better accuracy being achieved for finer grids. Isocentric doses were compared between Pinnacle(3)'s collapsed cone convolution algorithm and the Bentley-Milan algorithm within the Target-2 treatment planning system. Dose differences were generally less than 3% in the dose prescribed, with larger values for breast plans, where the Pinnacle(3) algorithm calculated scatter more accurately. Pelvic and thoracic plans were also verified using an anthropomorphic phantom, with local dose differences between calculated and delivered dose of up to 8%, but mainly less than 3%, and with no systematic difference. Ionization chamber verifications using START and RT-01 trial procedures demonstrated differences between calculated and measured doses of less than 2%. Following satisfactory performance in the commissioning process, Pinnacle(3) has now been introduced into routine clinical use.
描述了Pinnacle(3)治疗计划系统的调试过程。对四台医科达直线加速器进行了外照射光子调试。通过以下两种方法利用测量数据得出Pinnacle(3)射束模型的参数值:(1) 将加速器机头的蒙特卡罗模型与测量数据拟合,然后提取Pinnacle(3)射束模型的参数;(2) 使用Pinnacle(3)中的自动建模功能。这两种方法得出的剂量分布均符合已发表的建议。还创建了一个针对内部紧凑型遮挡系统定制的单独小射野射束模型,该模型满足立体定向引导适形脑部治疗的适当验收标准。还评估了非均匀、倾斜、不对称和不规则射野,计算剂量与测量剂量的偏差在±3%以内。对于4 mm×4 mm×4 mm的网格尺寸,发现剂量体积直方图计算在剂量或体积方面的误差在±5%以内,网格越精细,精度越高。在Target-2治疗计划系统中,比较了Pinnacle(3)的坍缩圆锥卷积算法和Bentley-Milan算法之间的等中心剂量。规定剂量中的剂量差异一般小于3%,乳腺计划中的差异值较大,其中Pinnacle(3)算法能更准确地计算散射。还使用人体模型对盆腔和胸部计划进行了验证,计算剂量与 delivered dose之间的局部剂量差异高达8%,但主要小于3%,且无系统差异。使用START和RT-01试验程序进行的电离室验证表明,计算剂量与测量剂量之间的差异小于2%。在调试过程中表现令人满意后,Pinnacle(3)现已引入常规临床使用。